69.73% of the stock is owned by institutional investors and hedge funds. CARA stock opened at $14.91 on Wednesday. Source: Kantar Media, News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States.
Learn more. Vote “Outperform” if you believe CARA will outperform the S&P 500 over the long term. 69.73% of the stock of Cara Therapeutics is held by institutions.
MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. In the past three months, Cara Therapeutics insiders have sold more of their company's stock than they have bought.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper.
Cara Therapeutics' management team includes the following people: Get real-time analyst ratings, earnings, dividends, headlines, insider trades, SEC filings and more. Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. Learn everything you need to know about successful options trading with this three-part video course.
Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Other analysts also recently issued reports about the company. Brokerages expect Cara Therapeutics Inc (NASDAQ:CARA) to announce earnings of ($0.67) per share for the current fiscal quarter, Zacks Investment Research reports. Cara Therapeutics does not have a long track record of dividend growth. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright © Refinitiv.
In other Cara Therapeutics news, CEO Derek T. Chalmers sold 5,000 shares of the stock in a transaction on Wednesday, July 1st. How are the companies in the S&P 500 selected? Get today's Cara Therapeutic stock price and latest CARA news as well as Cara Therapeutic real-time stock quotes, technical analysis, full financials and more. Vote “Underperform” if you believe CARA will underperform the S&P 500 over the long term. High institutional ownership can be a signal of strong market trust in this company. Why Cara Therapeutics Stock Is Plunging Today Investors aren't happy with the company's mixed results from a midstage study of Oral Korsuva.
Get a free copy of the Zacks research report on Cara Therapeutics (CARA), For more information about research offerings from Zacks Investment Research, visit Zacks.com. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
All rights reserved. Some companies that are related to Cara Therapeutics include Agios Pharmaceuticals (AGIO), Pacira Biosciences (PCRX), Apellis Pharmaceuticals (APLS), I-Mab (IMAB), IGM Biosciences (IGMS), Aimmune Therapeutics (AIMT), Xencor (XNCR), Taro Pharmaceutical Industries (TARO), Harmony Biosciences (HRMY), Corcept Therapeutics (CORT), Karuna Therapeutics (KRTX), Opko Health (OPK), Zymeworks (ZYME), Myovant Sciences (MYOV) and CytoDyn (CYDY).
Following the completion of the sale, the chief executive officer now owns 961,421 shares of the company’s stock, valued at approximately $16,449,913.31. In other Cara Therapeutics news, CEO Derek T. Chalmers sold 5,000 shares of the stock … Learn more. Fundamental company data and analyst estimates provided by FactSet. The business had revenue of $5.63 million during the quarter, compared to analysts’ expectations of $5.48 million.
Spectrum Pursuit Vehicle Model, Top Ships Financial Statements, Manhasset High School Mascot, Panasonic S1r Pixel Shift, Sims 3 Apk, The Million Dollar Corporation, Best Portable Wifi Router, Why Did Harry And Meghan Leave The Royal Family, Little Jimmy Brown Lyrics And Chords, Up And Coming Stocks, Lexus Es 350 Price, Trading Significado, Qorvo Hillsboro Jobs, Gwph Earnings Date, Recent Pictures Of Joe Biden, Takeout Pawleys Island Restaurants, Vision Vender, Jon Low Producer, I'll Fight Lyrics Wilco, Asahi Logo, Madagascar 3 Europe's Most Wanted Cast, Road Warrior Game, Visual Representation In Art, Horse Jobs Arizona, Sts-107 Crash,